A method for mass production of human coagulation factor VII derivatives, comprising: a) constructing an expression vector, comprising i) a nucleotide sequence of a dihydrofolate reductase promoter devoid of at least one CCGCCC repeat sequence from the GC-rich region thereof and a nucleotide sequence encoding a dihydrofolate reductase (DHFR) operably linked thereto, and ii) a nucleotide sequence of a cytomegalovirus early gene promoter and a nucleotide sequence encoding a human coagulation factor VII derivative operably linked thereto; b) transfecting an animal cell line with the expression vector of step a); c) culturing the transfected animal cell line of step b) in the presence of a dihydrofolate reductase inhibitor to select a cell line capable of expressing the human coagulation factor VII derivative with high efficiency; and d) culturing the animal cell line selected from step c) by adding at least one selected from the group consisting of sodium butyrate, vitamin K, and a culture medium supplement, wherein: when sodium butyrate is added: (i) the concentration of sodium butyrate is from 1.1 mM to 3.5 mM and the culture temperature of step d) is from 32.5°C to 35.0°C; or (ii) the concentration of sodium butyrate is from 1.2 mM to 2.0 mM and the culture temperature of step d) is from 31°C to 32.5°C; the culture medium supplement is soy hydrolysate or yeast extract; the human coagulation factor VII derivative has a partial sequence of SOD1 (superoxide dismutase 1) at the C-terminus of human coagulation factor VII; and vitamin K of step d) is vitamin K1. a) constructing an expression vector, comprising i) a nucleotide sequence of a dihydrofolate reductase promoter devoid of at least one CCGCCC repeat sequence from the GC-rich region thereof and a nucleotide sequence encoding a dihydrofolate reductase (DHFR) operably linked thereto, and ii) a nucleotide sequence of a cytomegalovirus early gene promoter and a nucleotide sequence encoding a human coagulation factor VII derivative operably linked thereto; b) transfecting an animal cell line with the expression vector of step a); c) culturing the transfected animal cell line of step b) in the presence of a dihydrofolate reductase inhibitor to select a cell line capable of expressing the human coagulation factor VII derivative with high efficiency; and d) culturing the animal cell line selected from step c) by adding at least one selected from the group consisting of sodium butyrate, vitamin K, and a culture medium supplement, wherein: when sodium butyrate is added: (i) the concentration of sodium butyrate is from 1.1 mM to 3.5 mM and the culture temperature of step d) is from 32.5°C to 35.0°C; or (ii) the concentration of sodium butyrate is from 1.2 mM to 2.0 mM and the culture temperature of step d) is from 31°C to 32.5°C; the culture medium supplement is soy hydrolysate or yeast extract; the human coagulation factor VII derivative has a partial sequence of SOD1 (superoxide dismutase 1) at the C-terminus of human coagulation factor VII; and vitamin K of step d) is vitamin K1. when sodium butyrate is added: (i) the concentration of sodium butyrate is from 1.1 mM to 3.5 mM and the culture temperature of step d) is from 32.5°C to 35.0°C; or (ii) the concentration of sodium butyrate is from 1.2 mM to 2.0 mM and the culture temperature of step d) is from 31°C to 32.5°C; the culture medium supplement is soy hydrolysate or yeast extract; the human coagulation factor VII derivative has a partial sequence of SOD1 (superoxide dismutase 1) at the C-terminus of human coagulation factor VII; and vitamin K of step d) is vitamin K1.